CRVO Company Profile and Key Details

CRVO has shown weak momentum, losing -7.91% over the past week and -1.27% over the past quarter, though year-to-date performance is down -11.52%. Short-term trend indicators are bullishly aligned (SMA20 -9.09%, SMA50 -31.38%, SMA200 -43.15%). The stock’s 14-day RSI is 36.08 (weak momentum), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -74.03% below its high and over 129.17% above its low. Average 10-day trading volume of 36.62 thousand shares is below the 3-month average of 70.73 thousand, indicating normal recent market interest.

CervoMed Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $9.08. This means the shares are trading below this model’s fair value.

CervoMed Inc. (NASDAQ:CRVO) closed at $3.70 USD, losing -$0.01 (-0.27%) from the previous close of $3.71. The stock is currently mid-range between its 52-week high and low $3.51 and $13.13. With a market capitalization of about $34.26 million, CervoMed Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-4.47). Key stats such as the average daily volume over the past year has been around 70.15 thousand shares, in line with its 52-week average. Headquartered in Boston, MA, CervoMed Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO John J. Alam, the company employs approximately 15 people and listed since May 23, 2008. CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases.

CervoMed Inc. has 8.70 million shares outstanding. The public float is 5.48 million shares, elevated short interest at 5.66% of float. This equals 331.39 thousand shares. The short ratio is 0.47 days. Institutional investors hold 34.34% of the float. Insiders own 31.4%. BOGER JOSHUA S holds 840.45 thousand shares, Winton Matthew has 15.00 thousand shares and Gregoire Sylvie has 12.50 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

CervoMed Inc. generated EPS of -$2.90 over the past year. Five-year average earnings growth is 56.66%. Wall Street analysts project EPS growth of 10.68% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 24 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $31.00 to $10.00. The high target offers 737.84% upside. The low target suggests 170.27% downside. The mean target is $23.28. This offers 529.19% upside. CervoMed Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 13, 2026, missed forecasts by 11.39%. The prior quarter beat by 23.53%. Over the last six quarters, Apple has recorded several small beats. These include 34.15% in November 12, 2024.

CervoMed Inc. trades at a P/E ratio of -1.3, slightly below the S&P 500 average, with a price-to-sales ratio of 108.5 and a price-to-book ratio of 1.92 suggesting the stock is closer to book value. The P/FCF stands at -1.49, also below market averages.

CervoMed Inc. (NASDAQ:CRVO) shares are down -11.52% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows CervoMed Inc. trading at a premium to the broader market with a P/E of -1.3. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $25.80, suggesting 597.3% upside. Our AI forecast model points to short-term weakness (-2.43% over two weeks), a medium-term fall (-90.81% over three months), and a longer-term loss (-78.65% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that CervoMed Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.43%, with price expected at $3.61 by May 18, 2026, within a range of $3.42 to $3.77 3-Month Outlook: Projected fall of -90.81%, reaching $0.34 by July 31, 2026, with a range of $0.00 to $0.82. 1-Year Outlook: Projected loss of -78.65%, with price at $0.79 by May 04, 2027, within a range of $0.00 to $0.00.